Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radotinib - Il-Yang

X
Drug Profile

Radotinib - Il-Yang

Alternative Names: IY-5511; IY5511HCl; Radotinib hydrochloride; Supect

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Il-Yang
  • Class Antineoplastics; Antiparkinsonians; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Parkinson's disease

Most Recent Events

  • 14 Jun 2024 Il-Yang plans a phase I pharmacokinetics trial (In volunteers) in South Korea (PO) (NCT06461078)
  • 21 Feb 2022 Phase-II clinical trials in Parkinson's disease (In adults) in France (PO) (NCT04691661)
  • 31 Dec 2020 Il-Yang plans a phase II trial for Parkinson's disease in France (PO) in January 2021 (NCT04691661)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top